Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does TIRZEPATIDE Cause Product dose omission issue? 3,211 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 3,211 reports of Product dose omission issue have been filed in association with TIRZEPATIDE (Zepbound). This represents 3.2% of all adverse event reports for TIRZEPATIDE.

3,211
Reports of Product dose omission issue with TIRZEPATIDE
3.2%
of all TIRZEPATIDE reports
0
Deaths
47
Hospitalizations

How Dangerous Is Product dose omission issue From TIRZEPATIDE?

Of the 3,211 reports, 47 (1.5%) required hospitalization, and 4 (0.1%) were considered life-threatening.

Is Product dose omission issue Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for TIRZEPATIDE. However, 3,211 reports have been filed with the FAERS database.

What Other Side Effects Does TIRZEPATIDE Cause?

Incorrect dose administered (23,301) Injection site pain (10,989) Nausea (10,018) Off label use (7,007) Extra dose administered (6,774) Diarrhoea (5,463) Vomiting (4,635) Injection site haemorrhage (4,389) Accidental underdose (3,897) Injection site erythema (3,844)

What Other Drugs Cause Product dose omission issue?

DUPILUMAB (18,189) USTEKINUMAB (9,405) GUSELKUMAB (9,267) LENALIDOMIDE (8,145) MEPOLIZUMAB (5,873) TOFACITINIB (5,646) VOXELOTOR (5,122) BELIMUMAB (4,671) SECUKINUMAB (4,572) APREMILAST (4,460)

Which TIRZEPATIDE Alternatives Have Lower Product dose omission issue Risk?

TIRZEPATIDE vs TISAGENLECLEUCEL TIRZEPATIDE vs TISLELIZUMAB TIRZEPATIDE vs TISOTUMAB VEDOTIN TIRZEPATIDE vs TISOTUMAB VEDOTIN-TFTV TIRZEPATIDE vs TITANIUM DIOXIDE\ZINC

Related Pages

TIRZEPATIDE Full Profile All Product dose omission issue Reports All Drugs Causing Product dose omission issue TIRZEPATIDE Demographics